A comparison of low- with high-osmolality contrast agents in cardiac angiography. Identification of criteria for selective use.
Authors:
- 1 January 1994
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 89 (1) , 291-301
Abstract
BACKGROUND Controversy exists as to whether low-osmolality radiographic contrast agents, which have less detrimental pharmacological effects but are considerably more expensive than high-osmolality agents, should be used universally or only for selected high-risk patients. METHODS AND RESULTS A randomized, double-blind study was used to compare the frequency and severity of adverse events in 2245 consecutive patients undergoing diagnostic cardiac angiography. Two thousand one hundred sixty-six patients were successfully randomized to either iohexol, a low-osmolality contrast agent, or diatrizoate (as Hypaque 76), a high-osmolality agent. The end point event included clinically important adverse events (which jeopardized the patient or required aggressive treatment), contrast agent-related procedure abbreviations, and conversion to open-label contrast agent. Clinically important end point events were associated with increased age, New York Heart Association functional class, left ventricular end-diastolic pressure, arteriovenous oxygen difference, severity of coronary artery disease, and history of a previous reaction to contrast agent. End point events were less frequent in patients receiving iohexol (2.6% versus 4.6%; adjusted odds ratio, 1.59; 95% confidence interval, 0.97-2.60; P = .07). The difference in event frequency between iohexol and diatrizoate was confined to the highest-risk quartile of the patient population. An algorithm was developed to classify patients as being at high or low risk for an event based on patient age, New York Heart Association class, history of a prior contrast reaction, and left ventricular end-diastolic pressure. Application of this algorithm for selective use of low-osmolality agents only for high-risk patients to a theoretical population of 1000 patients reduced contrast agent costs 66% without increasing the frequency of contrast agent-related adverse events. CONCLUSIONS The advantages of low-osmolality contrast agents are clinically important in patients with severe heart disease but are not in less ill patients. Universal use of low-osmolality agents for cardiac angiography in an unselected population is not necessary. Appropriately guided selective use of low-osmolality contrast agents is feasible and has the potential to reduce cost substantially without compromising safety or effectiveness.Keywords
This publication has 26 references indexed in Scilit:
- Randomized comparison of the cost and effectiveness of iopamidol and diatrizoate as contrast agents for cardiac angiographyJACC, 1990
- Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: Analysis of 8,517 patientsThe American Journal of Cardiology, 1990
- Hemodynamic and Electrocardiographic Effects of Ioversol During Cardiac AngiographyInvestigative Radiology, 1989
- SUBGROUP ANALYSISThe Lancet, 1988
- Contrast media-related complications during cardiac catheterization using HexabrixTM or RenografinTM in high-risk patientsThe American Journal of Cardiology, 1988
- Comparison of loxaglate with diatrizoate in angiography of the internal mammary arteryCatheterization and Cardiovascular Diagnosis, 1988
- Effects of a new nonionic and a conventional ionic contrast agent on coronary sinus ionized calcium and left ventricular hemodynamics in dogsJACC, 1985
- Clinical superiority of a new nonionic contrast agent (iopamidol) for cardiac angiographyJACC, 1985
- Hemodynamic and electrocardiographic effects in man of a new nonionic contrast agent (iohexol): Advantages over standard ionic agentsThe American Journal of Cardiology, 1983
- Hemodynamic changes after angiocardiography with a new low osmolar contrast medium (sodium‐meglumin‐joxaglat)Catheterization and Cardiovascular Diagnosis, 1983